Video

Dr. Feldman on the Significance of Active Surveillance in Prostate Cancer

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses the significance of active surveillance for patients with prostate cancer.

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses the significance of active surveillance for patients with prostate cancer.

Although, most men respond well to treatments for prostate cancer, there are significant adverse events to consider, explains Feldman.

Active surveillance is beneficial to a man whose prostate cancer may never affect him and help him to avoid potential side effects from treatment, states Feldman.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD